Barinthus Biotherapeutics PLC (BRNS)Healthcare | Biotechnology | Germantown, United States |
USD
|
Hot Take ↕ | Oct. 10, 2026, 2:13 p.m. UTC
The investment case here is fundamentally broken. The company is burning through cash with negative free cash flow and operating cash flow, while returning negative equity to shareholders. Despite trading at a discount to book value, the negative return on assets and equity indicate a deteriorating business rather than a bargain. There is no dividend to provide income, and the lack of analyst coverage combined with a 'no model' status for short-term forecasting suggests the market has effectively priced out any near-term catalysts. The stock is currently trapped in a low-price range with no visible path to recovery based on the available financial data. |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 18.019 |
| Market Cap | 30,232,266 |
| Forward P/E | -0.65 |
| Beta | -0.36 |
| Website | https://www.barinthusbio.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.33031672 |
| Address1 | 20,400 Century Boulevard |
| Address2 | Suite 210 |
| All Time High | 17.99 |
| All Time Low | 0.512 |
| Ask | 0.76 |
| Ask Size | 500 |
| Average Daily Volume10 Day | 60,300 |
| Average Volume | 49,739 |
| Average Volume10Days | 60,300 |
| Beta | -0.356 |
| Bid | 0.65 |
| Bid Size | 300 |
| Book Value | 1.397 |
| City | Germantown |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Currency | USD |
| Current Price | 0.7401 |
| Current Ratio | 5.539 |
| Date Short Interest | 1,788,134,400 |
| Day High | 0.7629 |
| Day Low | 0.6421 |
| Debt To Equity | 18.019 |
| Ebitda | -31,244,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | 0.599 |
| Enterprise Value | -18,706,734 |
| Exchange | NCM |
| Exchange Timezone Name | UTC |
| Fifty Day Average | 0.6455 |
| Fifty Two Week High | 1.83 |
| Fifty Two Week Low | 0.512 |
| Financial Currency | USD |
| First Trade Date Epoch Utc | 1,784,295,000 |
| Float Shares | 27,257,649 |
| Forward Eps | -1.135 |
| Forward P E | -0.6520705 |
| Free Cashflow | -6,171,375 |
| Full Time Employees | 14 |
| Fullday Change | -0.0189 |
| Fullday Change Percent | -0.0249012 |
| Fullday Price | 0.7401 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Gross Profits | 8,594,000 |
| Held Percent Insiders | 0.1981 |
| Held Percent Institutions | 0.44068 |
| Implied Shares Outstanding | 40,848,893 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Barinthus Biotherapeutics plc, together with its subsidiaries, engages in the research, development, and commercialization of immunotherapies and vaccines in the United States and the United Kingdom. The company develops VTP-1000, an antigen-specific immune tolerance candidate, which is in Phase I clinical trial to restore immune non-responsiveness to gluten in patients with celiac disease; and VTP-300, an immunotherapy, which is in Phase II clinical trial for the treatment of chronic hepatitis B virus infection. It has a license agreement with Oxford University Innovation for the development and commercialization of products with thermo-responsive adjuvant scaffolds; and U.S. National Institutes of Health for the evaluation of synthetic and polymer-based vaccine technology to prevent infectious disease and treat cancer in animal models. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is based in Germantown, Maryland. |
| Long Name | Barinthus Biotherapeutics PLC |
| Market Cap | 30,232,266 |
| Max Age | 86,400 |
| Message Board Id | finmb_366057508 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -41,767,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 30,232,265 |
| Number Of Analyst Opinions | 1 |
| Open | 0.7443 |
| Operating Cashflow | -26,425,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 443 917 0966 |
| Previous Close | 0.759 |
| Price Hint | 4 |
| Price To Book | 0.5297781 |
| Profit Margins | 0.0 |
| Quick Ratio | 5.333 |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Regular Market Day High | 0.7629 |
| Regular Market Day Low | 0.6421 |
| Regular Market Open | 0.7443 |
| Regular Market Previous Close | 0.759 |
| Regular Market Volume | 376,145 |
| Return On Assets | -0.18993 |
| Return On Equity | -0.52384996 |
| Sand P52 Week Change | 0.16207206 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 40,848,893 |
| Shares Percent Shares Out | 0.00029999999 |
| Shares Short | 13,211 |
| Shares Short Previous Month Date | 1,785,456,000 |
| Shares Short Prior Month | 45,910 |
| Short Name | Barinthus Biotherapeutics plc |
| Short Percent Of Float | 0.0005 |
| Short Ratio | 0.28 |
| State | MD |
| Symbol | BRNS |
| Target High Price | 6.0 |
| Target Low Price | 6.0 |
| Target Mean Price | 6.0 |
| Target Median Price | 6.0 |
| Time Zone Full Name | America/New_York |
| Time Zone Short Name | EDT |
| Total Cash | 59,295,000 |
| Total Cash Per Share | 1.452 |
| Total Debt | 10,295,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.02 |
| Trailing Peg Ratio | None |
| Two Hundred Day Average | 0.65839 |
| Underlying Symbol | BRNS |
| Uuid | 707a043e-fc69-36ad-8b44-afbf6d977172 |
| Volume | 376,145 |
| Website | https://www.barinthusbio.com |
| Zip | 20,874 |